Showing 4871-4880 of 10099 results for "".
- DermWire’s AD Pipeline Watch: TDM 180935 Performs Well in Phase 1 Studyhttps://practicaldermatology.com/news/dermwires-ad-pipeline-watch-tdm-180935-performs-well-in-phase-1-study/2462168/Technoderma Medicines, Inc. has completed a Phase 1 clinical trial of TDM-180935 topical ointment for Atopic Dermatitis (AD). TDM 180935 is a small molecule drug candidate that functions as a potent JAK1/Tyk2 small molecule inhibitor. Preclinical assessment of TDM-180935 has demon
- FDA Accepts Arcutis’ sNDA for Roflumilast Cream 0.15% for Treatment of AD in Adults and Children Down to Age 6https://practicaldermatology.com/news/fda-accepts-arcutis-snda-for-roflumilast-cream-015-for-treatment-of-ad-in-adults-and-children-down-to-age-6/2462159/The U.S. Food and Drug Administration (FDA) has accepted Arcutis’ supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid
- Regenerative Medicine in Action: Reprogramming Tissue Mechanically to Heal Wounds, Rejuvenate Skinhttps://practicaldermatology.com/news/regenerative-medicine-in-action-reprogramming-tissue-mechanically-to-heal-wounds-rejuvenate-skin/2462156/Researchers have taken connective tissue cells that have been mechanically reprogrammed to resemble stem cells and transplanted them into damaged skin. In their laboratory experiment, they were able to show that the skin tissue model can actually be rejuvenated and that injur
- Beyond the Headlines: Dr. Jonathan Silverberg Reviews Maintenance Data on Rademikibart From a Pivotal Trial in Chinahttps://practicaldermatology.com/news/beyond-the-headlines-dr-jonathan-silverberg-reviews-maintenance-data-on-rademikibart-from-a-pivotal-trial-in-china/2462152/DermWire recently reported positive topline results from a 52-week maintenance study of rademikibart in people with atopic dermatitis (AD). At
- First Patients Enrolled in Phase 2 Proof of Concept Trial of MC2-25 VLS in Vulvar Lichen Sclerosushttps://practicaldermatology.com/news/first-patients-enrolled-in-phase-2-proof-of-concept-trial-of-mc2-25-vls-in-vulvar-lichen-sclerosus/2462151/The first patients have been enrolled in a Phase 2a proof of concept trial evaluating the safety and efficacy of MC2-25 VLS, a new drug candidate for the treatment of urea- associated skin diseases, including vulvar lichen sclerosus. MC2-25 VLS is a based on a di-peptide that
- Melanoma and Lung Cancer Drug May Also Treat Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/melanoma-and-lung-cancer-drug-may-also-treat-cutaneous-squamous-cell-carcinoma/2462149/Plixorafenib, a new drug developed for treating melanoma and lung cancer, may also stop the progression of cutaneous squamous cell carcinoma, new research suggests. Researchers out of the University of Turku, Finland, discovered that plixorafenib (also called PLX8394) simultaneously inh
- Unmet Needs in Dermatology: NFX-179 Topical Gel May Shrink Cutaneous Neurofibromas in NF1 Patientshttps://practicaldermatology.com/news/unmet-needs-in-dermatology-nfx-179-topical-gel-may-shrink-cutaneous-neurofibromas-in-nf1-patients/2462134/NFX‑179 Gel produced a statistically significant improvement over vehicle in the shrinkage of cutaneous neurofibromas in people with neurofibromatosis type 1 (NF1), according to positive topline results from a Phase 2b clinical trial. Cutaneous neurofibromas (cNFs) appear in over 9
- Phase 1 Data: Kymera Therapeutics’ IRAK4 Degrader Shows Promise in AD, HShttps://practicaldermatology.com/news/phase-1-data-kymera-therapeutics-irak4-degrader-shows-promise-in-ad-hs/2462133/Kymera Therapeutics, Inc. KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader, is showing early promise in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), according to a Phase 1 Trial
- ACR: TREMFYA Improves Pain, Physical Function and Fatigue in PsA Patients Through Six Monthshttps://practicaldermatology.com/news/acr-tremfya-improves-pain-physical-function-and-fatigue-in-psa-patients-through-six-months/2462121/Substantial numbers of people living with treatment-resistant active PsA who used TREMFYA (guselkumab) in real-world settings reported meaningful improvements in pain, physical function and fatigue through six months, according to new data from the CorEvitas Psoriatic Arthritis (PsA) and Spo
- Survey: Americans with Mild-to-Moderate Acne Have Defeatist Attitudes About Treatment, Despite Self-Consciousnesshttps://practicaldermatology.com/news/sun-pharma-survey-reveals-americans-with-mild-to-moderate-acne-have-defeatist-attitudes-about-treatment-despite-self-consciousness/2462110/A new survey reveals defeatist attitudes about treatment among people with mild-to-moderate acne, despite feelings of self-consciousness. Among the 1,003 survey respondents ages 13-55, only three in 10 reported having seen a dermatologist, suggesting that many people with mild-to-moderate acne ar